인디아 글로벌라이제이션 캐피털(IGC)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.30 (+1.29%), 시가총액 $0.03B, 52주 범위 $0.25 ~ $0.47.
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was
인디아 글로벌라이제이션 캐피털의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
인디아 글로벌라이제이션 캐피털의 현재 주가는 $0.30 (+1.29%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
인디아 글로벌라이제이션 캐피털의 시가총액은 약 $0.03B입니다.
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in th